A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT04849364

Study Contact: studies@hoosiercancer.org; (317) 921-2050.